Press release
Thyroid Cancer Pipeline 2024 | AffyImmune Therapeutics, Suzhou Zelgen Biopharmaceuticals, Bristol-Myers Squibb, Suzhou NeuPharma, AstraZeneca, Verastem Oncology, Thryv Therapeutics
Discover the latest drugs and treatment options in the Thyroid Cancer Pipeline. Dive into DelveInsight's comprehensive report today! @ Thyroid Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/thyroid-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Thyroid Cancer Pipeline Report
* July 2024:- Istituti Clinici Scientifici Maugeri SpA - This window of opportunity trial is studying a checkpoint inhibitor agent to treat differentiated thyroid cancer in a neoadjuvant setting. A checkpoint inhibitor is a compound aimed at restoring tumor immunosurveillance. The name of this agent is pembrolizumab.
* July 2024:- ModeX Therapeutics, An OPKO Health Company- A Phase 1/2a, Multicenter, First-in-human, Open-label Clinical Trial Evaluating MDX2001 Monotherapy in Patients With Advanced Solid Tumors. This study consists of Phase 1a dose escalation, Phase 1b dose expansion in a single indication, and Phase 2a expansion in a single indication. This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
* DelveInsight's Thyroid Cancer pipeline report depicts a robust space with 50+ active players working to develop 51+ pipeline therapies for Thyroid Cancer treatment.
* The leading Thyroid Cancer Companies such as AffyImmune Therapeutics, Suzhou Zelgen Biopharmaceuticals, Bristol-Myers Squibb, Suzhou NeuPharma, AstraZeneca, Verastem Oncology, Thryv Therapeutics, Molecular Targeting Technologies, Chimerix, Codiak BioSciences, LeadArtis, Tyra Biosciences, Roche, Sichuan Kelun-Biotech Biopharmaceutical, Advenchen Laboratories, and others.
* Promising Thyroid Cancer Therapies such as Selpercatinib, Cabozantinib, Vandetanib, E7080 Capsule, Lenvatinib (DTC Cohort), Irofulven + capecitabine, XL184, AL2846 Capsule, and others.
Stay ahead with the most recent pipeline outlook for Thyroid Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Thyroid Cancer Approved Drugs [https://www.delveinsight.com/sample-request/thyroid-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Thyroid Cancer Emerging Drugs
* rhTSH: Suzhou Zelgen Biopharmaceuticals
Recombinant human TSH (rhTSH) was developed to provide TSH stimulation without the requirement for THST withdrawal and the resultant metabolic disturbance, and without the drawbacks associated with the use of bovine TSH. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with thyroid cancer.
* Nivolumab: Bristol-Myers Squibb
Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with thyroid cancer.
* RX208: Suzhou NeuPharma
RX208 is a potential "best-in-class" BRAF V600E inhibitor with a proprietary novel chemical structure that is different from other marketed BRAF inhibitors. It exhibited high bioavailability and excellent anti-tumor efficacy in preclinical studies. Early clinical data demonstrated preliminary efficacy and good safety and tolerability in patients with cancer, warranting further clinical development. The drug is currently being evaluated under Phase I/II clinical trial for the treatment of patients with thyroid cancer.
* AIC100: AffyImmune Therapeutics
AffyImmune's lead product, AIC100, is an affinity-tuned, ICAM-1 targeted, third generation CAR T cell therapy. AIC100's CAR has an affinity to ICAM-1 similar to the affinity between naturally-occurring T cells and their targets, which is much lower than most CARs used to date and reduces on-target off-tumor toxicities. AIC100 also expresses SSTR2 for real-time monitoring of CAR T cell distribution and activity. Preclinical studies demonstrate that AIC100 induces robust and enduring tumor eradication without toxicity-related relapse or fatality in various solid tumor models. Studies also suggest the potential for combination with anti-PD-1 therapies. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with Thyroid Cancer.
Explore groundbreaking therapies and clinical trials in the Thyroid Cancer Pipeline. Access DelveInsight's detailed report now! @ Thyroid Cancer Treatment Drugs [https://www.delveinsight.com/sample-request/thyroid-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Thyroid Cancer Drugs and Companies
* Rosiglitazone: Exelixis
* Lenvatinib: Eisai Limited
* Ifosfamide: Merck Sharp & Dohme LLC
Thyroid Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Intravenous
* Subcutaneous
* Oral
* Intramuscular
Thyroid Cancer Products have been categorized under various Molecule types such as
* Monoclonal antibody
* Small molecule
* Peptide
Unveil the future of Thyroid Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Thyroid Cancer Market Drivers and Barriers [https://www.delveinsight.com/sample-request/thyroid-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Thyroid Cancer Pipeline Report
* Coverage- Global
* Thyroid Cancer Companies such as AffyImmune Therapeutics, Suzhou Zelgen Biopharmaceuticals, Bristol-Myers Squibb, Suzhou NeuPharma, AstraZeneca, Verastem Oncology, Thryv Therapeutics, Molecular Targeting Technologies, Chimerix, Codiak BioSciences, LeadArtis, Tyra Biosciences, Roche, Sichuan Kelun-Biotech Biopharmaceutical, Advenchen Laboratories, and others.
* Thyroid Cancer Therapies- Selpercatinib, Cabozantinib, Vandetanib, E7080 Capsule, Lenvatinib (DTC Cohort), Irofulven + capecitabine, XL184, AL2846 Capsule, and others.
* Thyroid Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Thyroid Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Thyroid Cancer Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Thyroid Cancer Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/thyroid-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Thyroid Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Thyroid Cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* rhTSH: Suzhou Zelgen Biopharmaceuticals
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Nivolumab: Bristol-Myers Squibb
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* AIC100:Affyimmune Therapeutics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Thyroid Cancer Key Companies
* Thyroid Cancer Key Products
* Thyroid Cancer- Unmet Needs
* Thyroid Cancer- Market Drivers and Barriers
* Thyroid Cancer- Future Perspectives and Conclusion
* Thyroid Cancer Analyst Views
* Thyroid Cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=thyroid-cancer-pipeline-2024-affyimmune-therapeutics-suzhou-zelgen-biopharmaceuticals-bristolmyers-squibb-suzhou-neupharma-astrazeneca-verastem-oncology-thryv-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Thyroid Cancer Pipeline 2024 | AffyImmune Therapeutics, Suzhou Zelgen Biopharmaceuticals, Bristol-Myers Squibb, Suzhou NeuPharma, AstraZeneca, Verastem Oncology, Thryv Therapeutics here
News-ID: 3577497 • Views: …
More Releases from ABNewswire
Vidsoul Launches to Offer a Superior Pixverse AI Experience Within an All-in-One …
Hong Kong - September 18, 2025 - Vidsoul [https://www.vidsoul.ai/video-generate?type=image-to-video&modelId=4003&prompt=girl]today announced the official launch of its comprehensive AI creative platform, strategically designed to be the ultimate destination for digital artists and a superior home for users of the popular Pixverse AI model. By integrating the latest Pixverse v4.5 engine alongside other industry titans like Google Veo 3 and Kling AI, Vidsoul directly solves the critical issue of workflow fragmentation. The platform…
Empowering Minds at the Kitchen Table: Wilda Mills Releases Groundbreaking Book …
Image: https://www.abnewswire.com/upload/2025/09/b71f8d5385e31eed07d79a4ab4e8d1bd.jpg
Health care practitioner, therapist, and pastor Wilda Mills has written a motivating new book that deals with one of the most critical problems of today: the degeneration of mental resilience in youth and families. In her groundbreaking book, "Rewiring the Brain at the Kitchen Table," Mills offers readers hands-on, science-based methods grounded in the principles of neuroplasticity. Her goal is to provide families with skills for mental, emotional, and…
Shehds Announces Fall Sale with Exciting New Arrivals in Stage Lighting
During the fall sale, Shehd is offering 10% discounts.
Image: https://www.abnewswire.com/upload/2025/09/b95f350fffd19d78d9a3ee386be479d2.jpg
SHEHDS, a leading manufacturer of professional stage lighting, is celebrating the season with a Fall Sale offering 10% off across select products. Adding to the excitement, the company has introduced two powerful and innovative lighting solutions: the ShockCore Waterproof LED 350W 12-Pixel Strobe Light Zero Noise Outdoor and the ShockCore Waterproof Spliced LED 250W 16-Pixel Strobe Light Zero Noise. Both arrivals…
Social Security Trust Fund Depletion Accelerated to 2032-2034: A Breakdown of th …
Social Security depletion accelerated to 2032-34. Recent laws may trigger 20% benefit cuts for 69M Americans. $2,000 benefits right $1,600. Expert: '$25 trillion deficit solvable but time running out.' Analysis reveals how well-intentioned legislation inadvertently accelerated the crisis timeline.
Toms River, NJ - A new analysis [https://medium.com/@press_52522/social-securitys-2025-trustees-report-what-retirees-need-to-know-2a6e8af501f0] of the 2025 Social Security Board of Trustees report shows recent legislative action has sped up the date of the trust fund depletion to…
More Releases for Thyroid
Rising Incidences of Thyroid Disorders Fuel Growth In The Thyroid Function Test …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Thyroid Function Test Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for thyroid function tests has witnessed substantial growth in the past few years. The market is projected to expand from $1.7 billion in 2024 to $1.81 billion in 2025, with an…
Rising Incidences of Thyroid Disorders Fuel Growth In The Thyroid Function Test …
The Thyroid Function Test Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Thyroid Function Test Market Size During the Forecast Period?
The thyroid function test market has grown significantly in recent years. It is expected to grow from $1.7 billion in 2024…
Thyroid Function Test Market Report 2024 - Thyroid Function Test Market Growth A …
"The Business Research Company recently released a comprehensive report on the Global Thyroid Function Test Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive…
Thyroid Ablation Devices Market
Alarming rise in prevalence of thyroid cancer, advancements in thyroid ablation system, rise in government & private funds for development of healthcare sectors, and increase in number of thyroid nodule cases are expected to notably contribute toward the growth of the global thyroid ablation devices market during the forecast period.
Rise in prevalence of thyroid cancer and thyroid nodules, demand for minimally invasive procedures, and technological advancements in ablation devices drive…
Thyroid Gland Disorders Treatment Market Increasing incidence of Autoimmune Dise …
The global market for thyroid gland disorders features a consolidated vendor landscape with a handful of companies accounting for a major chunk of the global market, observes Transparency Market Research in a recent report. In 2016, the thyroid gland disorders treatment market was dominated by Merck KGaA and AbbVie, Inc., which collectively accounted for more than half of the market. It has been observed that despite the large pool of…
Increasing Incidence of Thyroid Gland Disorders Expected to Propel the Thyroid G …
Thyroid gland is made of thyroid cells that absorb iodine from food and convert it into triiodothyronine (T3) and thyroxine (T4). These hormones are released into the blood stream and play an important role in the regulation of metabolism. Thyroid gland disorders are defined as an abnormal release of thyroid hormones which may demand proper therapeutic agents to correct the disorder condition. This report studies the market in a view…
